Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

Korábbi kezelés

• Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents

Más betegség

• Patients who have been diagnosed with any neuro-cognitive disorder including traumatic brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and Creutzfeldt-Jakob disease.

Egyéb

• Patients having mental incompetence as assessed by study PI, which would hinder completion of the surveys
• Pregnant or breastfeeding
• Any known brain metastases
• Non-English speaking patients
• Patients deemed inappropriate to participate in this study by the study PI or coordinator will be excluded.

• Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior to study-specific screening procedures. Must be able to provide study-specific informed consent prior to study entry.
• A histologically-confirmed colorectal tumor
• Patients who will be treated with cytotoxic chemotherapies including Capecitabine, Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.
• Patients must not have received cytotoxic chemotherapy previous to enrollment.